Hormonal regulation of B-cell function and systemic lupus erythematosus

Lupus

Volumn 17, Issue 6, 2008, Pages 528-532

  Cohen Solal, J F G ^a   Jeganathan, V ^a   Hill, L ^a   Kawabata, D ^a   Rodriguez Pinto, D ^a   Grimaldi, C ^a   Diamond, B ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Auto antibodies; B cells; Mouse model; Oestrogen; Prolactin

Indexed keywords

AUTOANTIBODY; CYTOKINE; DOUBLE STRANDED DNA; ESTRADIOL; ESTROGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; ORAL CONTRACEPTIVE AGENT; PROLACTIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOPOIESIS; NONHUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANDROGENS; ANIMALS; B-LYMPHOCYTES; ESTROGENS; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPOIESIS; RISK FACTORS;

EID: 46849085591     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308089402     Document Type: Review

References (65)

1. Boumpas, DT, Austin, HA, Fessler, BJ, Balow, JE, Klippel, JH, Lockshin, MD. Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940-950.
2. Cervera, R, Khamashta, MA, Font, J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113-124.
3. Cohen-Solal, JF, Jeganathan, V, Grimaldi, CM, Peeva, E, Diamond, B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006; 305: 67-88.
4. Medina, KL, Smithson, G, Kincade, PW. Suppression of B lymphopoiesis during normal pregnancy. J Exp Med 1993; 178: 1507.
5. Medina, KL, Kincade, PW. Pregnancy-related steroids are potential regulators of B lymphopoiesis. Proc Natl Acad Sci USA 1994; 91: 5382.
6. Masuzawa, T, Miyaura, C, Onoe, Y, et al. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 1994; 94: 1090-1097.
7. Viselli, SM, Reese, KR, Fan, J. Kovacs, WJ, Olsen, NJ. Androgens alter B cell development in normal male mice. Cell Immunol 1997; 182: 99-104.
8. Ellis, TM, Moser, MT, Le, PT, Flanigan, RC, Kwon, ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 2001; 13: 553-558.
9. Miyaura, C, Onoe, Y, Inada, M, et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 1997; 94: 9360-9365.
10. Smithson, G, Beamer, WG, Ponting, I, Kincade, PW. Estrogen suppresses stromal cell-dependent lymphopoiesis in culture. J Immunol 1995; 155: 3409.
11. Olsen, NJ, Gu, X, Kovacs, WJ. Bone marrow stromal cells mediate androgenic suppression of B lymphocyte development. J Clin Invest 2001; 108: 1697-1704.
12. Offen, D, Spatz, L, Escowitz, H, Factor, S, Diamond, B. Induction of tolerance to an IgG autoantibody. Proc Natl Acad Sci USA 1992; 89: 8332-8336.
13. Spatz, L, Saenko, V, Iliev, A, Jones, L, Geskin, L, Diamond, B. Light chain usage in anti-double-stranded DNA B cell subsets: role in cell fate determination. J Exp Med 1997; 185: 1317-1326.
14. Bynoe, MS, Spatz, L, Diamond, B. Characterization of anti-DNA B cells that escape negative selection. Eur J Immunol 1999; 29: 1304-1313.
15. Kuo, P, Bynoe, MS, Wang, C, Diamond, B. Bc1-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol 1999; 29: 3168-3178.
16. Medina, KL, Garrett, KP, Thompson, LF, Rossi, MI, Payne, KJ, Kincade, PW. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001; 2: 718-724.
17. Grimaldi, CM, Michael, DJ, Diamond, B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001; 167: 1886-1890.
18. Grimaldi, CM, Cleary, J, Dagtas, AS, Moussai, D, Diamond, B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109: 1625-1633.
19. Grimaldi, CM, Jeganathan, V, Diamond, B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176: 2703-2710.
20. Shaw, PX, Horkko, S, Chang, MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-1740.
21. Hande, S, Notidis, E, Manser, T. Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development. Immunity 1998; 8: 189-198.
22. Grimaldi, CM, Hicks, R, Diamond, B. B cell selection and susceptibility to autoimmunity. J Immunol 2005; 174: 1775-1781.
23. Morales, P, Carretero, MV, Geronimo, H, et al. Influence of prolactin on the differentiation of mouse B-lymphoid precursors. Cell Growth Differ 1999; 10: 583-590.
24. Steger, RW, Chandrashekar, V, Zhao, W, Bartke, A, Horseman, ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 1998; 139: 3691-3695.
25. Bouchard, B, Ormandy, CJ, Di Santo, JP, Kelly, PA. Immune system development and function in prolactin receptor-deficient mice. J Immunol 1999; 163: 576-582.
26. McMurray, R, Keisler, D, Izui, S, Walker, SE. Hyperprolactinemia in male NZB/NZW (BAV) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 1994; 71: 338-343.
27. McMurray, R, Keisler, D, Kanuckel, K, Izui, S, Walker, SE. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147: 3780-3787.
28. Peeva, E, Michael, D, Cleary, J, Rice, J, Chen, X, Diamond, B. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003; 111: 275-283.
29. Ratkay, LG, Weinberg, J, Waterfield, JD. The effect of lactation in the post-partum arthritis of MRL-lpr/fasmice. Rheumatology (Oxford) 2000; 39: 646-651.
30. Walker, SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus 2001; 10: 762-768.
31. Peeva, E, Grimaldi, C, Spatz, L, Diamond, B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000; 106: 1373-1379.
32. Venkatesh, J, Peeva, E, Xu, X, Diamond, B. Cutting edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J Immunol 2006; 176: 3311-3314.
33. Peeva, E, Venkatesh, J, Michael, D, Diamond, B. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother 2004; 58: 310-319.
34. Neidhart, M. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Biomed Pharmacother 1997; 51: 118-125.
35. Inui, A, Ogasawara, H, Naito, T, et al. Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Clin Rheumatol 2007; 26: 1675-1678.
36. Phiel, KL, Henderson, RA, Adelman, SJ, Elloso, MM. Differential estrogen receptor gene expression in human peripheral blood mono-nuclear cell populations. Immunol Lett 2005; 97: 107-113.
37. Kanda, N, Tamaki, K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999; 103: 282-288.
38. Evans, MJ, MacLaughlin, S, Marvin, RD, Abdou, NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Clin Immunol Immunopathol 1997; 82: 258-262.
39. Sandi, C, Cambronero, JC, Borrell, J, Guaza, C. Mutually antagonistic effects of corticosterone and prolactin on rat lymphocyte proliferation. Neuroendocrinology 1992; 56: 574-581.
40. Krumenacker, JS, Buckley, DJ, Leff, MA, et al. Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression. Endocrine 1998; 9: 163-170.
41. Allen, SH, Sharp, GC, Wang, G, et al. Prolactin levels and antinu-clear antibody profiles in women tested for connective tissue disease. lupus 1996; 5: 30-37.
42. Gutierrez, MA, Molina, JF, Jara, LJ, et al. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Int Arch Allergy Immunol 1996; 109: 229-235.
43. Jacobi, AM, Rohde, W, Volk, HD, Dorner, T, Burmester, GR, Hiepe, F. Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls. Ann Rheum Dis 2001; 60: 242-247.
44. Cesario, TC, Yousefi, S, Carandang, G, Sadati, N, Le, J, Vaziri, N. Enhanced yields of gamma interferon in prolactin treated human peripheral blood mononuclear cells. Proc Soc Exp Biol Med 1994; 205: 89-95.
45. Roubinian, JR, Talal, N, Greenspan, JS, Goodman, JR, Siiteri, PK. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979; 63: 902-911.
46. Carlsten, H, Tarkowski, A, Holmdahl, R, Nilsson, LA. Oestrogen is a potent disease accelerator in SLE-prone MRL-lpr/lpr mice. Clin Exp Immunol 1990; 80: 467-473.
47. Carlsten, H, Nilsson, N, Jonsson, R, Backman, K, Holmdahl, R, Tarkowski, A. Estrogen accelerates immune complex glomerulone-phritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL-lpr/lpr mice. Cell Immunol 1992; 144: 190-202.
48. Dhaher, YY, Greenstein, BD, Khamashta, MA, Hughes, GR. Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomised Balb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE). Autoimmunity 2001; 33: 237-243.
49. Auborn, KJ, Qi, M, Yan, XJ, et al. Lifespan is prolonged in autoimmune-prone (NZB/NZW) F1 mice fed a diet supplemented with indole-3-carbinol. J Nutr 2003; 133: 3610-3613.
50. Pimstone, BL. S.L.E. cells after oral contraceptives. Lancet 1968; 25: 1153.
51. Chapel, TA, Burns, RE. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 1971; 110: 366-369.
52. Travers, RL, Hughes, GR. Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 1978; 5: 448-451.
53. Garovich, M, Agudelo, C, Pisko, E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1980; 23: 1396-1398.
54. Furukawa, F, Tachibana, T, Imamura, S, Tamura, T. Oral contraceptive-induced lupus erythematosus in a Japanese woman. J Dermatol 1991; 18: 56-58.
55. Barrett, C, Neylon, N, Snaith, ML. Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 1986; 25: 300-301.
56. Jungers, P, Liote, F, Dehaine, V, et al. [Hormonal contraception and lupus] in French. Ann Med Interne (Paris) 1990; 141: 253-256.
57. Julkunen, HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20: 427-433.
58. Buyon, JP, Belmont, HM, Kalunian, KC. Postmenopausal hormone therapy and systemic lupus erythematosus. Ann Intern Med 1995; 123:961.
59. Arden, NK, Lloyd, ME, Spector, TD, Hughes, GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3: 11-13.
60. Kreidstein, S, Urowitz, MB, Gladman, DD, Gough, J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 2149-2152.
61. Mok, CC, Lau, CS, Ho, CT, Lee, KW, Mok, MY, Wong, RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 342-346.
62. Sanchez-Guerrero, J, Liang, MH, Karlson, EW, Hunter, DJ, Coldir/. GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430-433.
63. Sanchez-Guerrero, J, Karlson, EW, Liang, MH, Hunter, DJ, Speizcr. FE, Colditz, GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40: 804-808.
64. Buyon, JP, Petri, MA, Kim, MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953-962.
65. Petri, M, Kim, MY, Kalunian, KC, et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-2558.